Due to PTEN depletion, PIK3CA amplification, and other genetic changes, the PI3K-Akt-mTOR pathway is most frequently overactivated in prostate cancer [5, 7, 8], which is associated with cancer progression, cancer metastasis, as well as development of drug resistance [5, 7, 8]. This evidence concerns the gene PTEN and prostate carcinoma.